Puma Biotechnology Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies aimed at treating cancer. Its primary focus centers on enhancing cancer treatment through advanced pharmaceutical interventions, particularly targeting breast cancer and other tumors that overexpress the HER2 protein. A key product in Puma Biotechnology's portfolio is neratinib, an oral medication designed to inhibit cancer cell proliferation by interfering with the HER2/neu and EGFR kinases. This compound represents a significant stride in oncology, particularly as it's suited for patients with early-stage and metastatic HER2-positive breast cancer. Puma Biotechnology's impact resonates across the healthcare sector, providing groundbreaking therapeutic solutions that address unmet medical needs. Its operational strategies and clinical advancements position it as an influential player in the pharmaceutical and healthcare industries. Founded in 2010 and headquartered in Los Angeles, California, the company continues to contribute to the global cancer treatment landscape through research and strategic partnerships, aiming to improve patient outcomes and redefine standard care protocols in oncology.